SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Neuland Laboratories reports Profit after tax of Rs 98.41 Mln, in the June 2022 quarter

03 Aug 2022 Evaluate
The revenue for the June 2022 quarter is pegged at Rs. 2211.70 millions, about 10.10% up against Rs. 2008.87 millions recorded during the year-ago period.Net profit stood at Rs. 98.41  millions  compared to Rs. 86.48 millions in the corresponding previous quarter,high by 13.80%.OP of the company witnessed a marginal growth to 289.90 millions from 276.58 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 2211.70 2008.87 10.10 2211.70 2008.87 10.10 9510.77 9369.13 1.51
Other Income 5.12 20.56 -75.10 5.12 20.56 -75.10 20.77 160.95 -87.10
PBIDT 289.90 276.58 4.82 289.90 276.58 4.82 1442.70 1625.38 -11.24
Interest 28.58 38.43 -25.63 28.58 38.43 -25.63 134.94 178.98 -24.61
PBDT 261.32 238.15 9.73 261.32 238.15 9.73 1307.76 1446.40 -9.59
Depreciation 127.98 118.28 8.20 127.98 118.28 8.20 490.36 396.78 23.58
PBT 133.34 119.87 11.24 133.34 119.87 11.24 817.40 1049.62 -22.12
TAX 34.93 33.39 4.61 34.93 33.39 4.61 182.06 246.67 -26.19
Deferred Tax -6.07 0.13 -4769.23 -6.07 0.13 -4769.23 -22.16 121.84 -118.19
PAT 98.41 86.48 13.80 98.41 86.48 13.80 635.34 802.95 -20.87
Equity 129.00 129.00 0.00 129.00 129.00 0.00 129.00 129.00 0.00
PBIDTM(%) 13.11 13.77 -4.80 13.11 13.77 -4.80 15.17 17.35 -12.56

Neuland Laboratories Share Price

15140.00 -161.65 (-1.06%)
20-Apr-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1226.10
Cipla 1228.55
Zydus Lifesciences 935.00
Lupin 2326.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×